RESPIVIR and its technological platform Virnext conduct collaborative and interdisciplinary research aimed at developing and validating, across a continuum of preclinical in vitro and in vivo models, new prophylactic and therapeutic strategies against emerging and re-emerging respiratory viral infections. In the latest issue (#63) of the INSERM magazine, the article by Pascal Nguyên highlights the translational research of our international joint laboratory RESPIVIR (France–Canada), as well as its valorization through technology transfer and the creation of spin-offs such as AIS Biotech.
The article notably emphasizes our collaborative program with CERMAV, an expert in scalable bioproduction processes for complex polysaccharides. Funded by Linksium, this partnership led to the identification and in vivo preclinical validation of #Glycoflu, the first compound from a new class of biomolecules acting as decoy receptors that prevent human influenza viruses from attaching to respiratory epithelial cells.
Protected by a European patent (EP21305131.1) filed by Inserm, Université Claude Bernard Lyon 1, CNRS, ENS de Lyon, and Université Grenoble Alpes, the synthetic complex glycopolymer #Glycoflu has been licensed to AIS Biotech, which is now advancing its clinical development.
This new strategy, based on tailor-made synthetic complex glycopolymers, represents a complementary approach to vaccination and conventional antivirals in the fight against seasonal and potentially pandemic influenza, notably by helping to limit viral transmission and the emergence of resistance.
Many thanks to Inserm and the entire editorial team of its magazine for highlighting #RESPIVIR.
Link to the article (pp. 40–41) #Entreprendre
https://www.calameo.com/read/0051544500432de1d8276
For more information:
https://virnext.fr/
https://respivir.io/
https://cermav.cnrs.fr/
https://ais-biotech.com/
Aurélie JUHEM, Marion Pastor, Emeline Millot, Richard Jean-Guillaume Lafay, Aurélien Traversier, Emilie Laurent